The COVID-19 Roller Coaster is a wild ride! Strap yourself in and hold on for the ride of…
On Nov. 26, 2021, Merck provided an update on the MOVe-OUT study of molnupiravir, an investigational oral antiviral…
On Nov. 18, 2021, Pfizer announced an agreement with the U.S. government to supply 10 million treatment courses…
On Nov. 17, 2021, Jubilant HollisterStier broke ground for our $285 million Spokane facility expansion. This expansion is…
On Nov. 17, 2021, Pacific Northwest National Laboratory (PNNL) announced researchers had compiled the most comprehensive road map…
On Nov. 17, 2021, GlaxoSmithKline and Vir Biotechnology announced U.S. government contracts totalling approximately $1 billion (USD) to…
On Nov. 16, 2021, Illumina and Genetic Alliance announced the creation of the iHope Genetic Health program aimed…
On Nov. 16, 2021, Pfizer announced it had submitted an Emergency Use Authorization (EUA) of its investigational oral…
On Nov. 14, 2021, the Calgary city council voted to reinstate fluoridation in Calgary’s waters. The count was…
On Nov. 12, 2021, with COVID-19 infections surging worldwide, a united group of 18 companies representing a large…
On Nov. 8, 2021, Regeneron announced that the European Commission had approved the casirivimab and imdevimab antibody cocktail,…
On Nov. 8, 2021, Cocrystal Pharma announced that its SARS-CoV-2 main protease inhibitors showed potent in vitro pan-viral…
On Nov. 5, 2021, the USDA’s (USDA) National Veterinary Services Laboratories announced confirmation of SARS-CoV-2 in two spotted…
On Nov. 5, 2021, Pfizer announced it was investigational novel COVID-19 oral antiviral candidate, PAXLOVID, significantly reduced hospitalization…
On Nov. 5, 2021, Chugai Pharmaceutical, announced that it had obtained approval from the Ministry of Health, Labour…
On Oct. 29, 2021, Oregon Health & Science University’s (OHSU) board of directors approved a project to expand…
On Oct. 28, 2021, Pfizer and BioNTech announced that the U.S. government had purchased 50 million more doses…
On Oct. 26, 2021, Vaxart announced that it has dosed the first subject in its Phase II COVID-19…
On Oct. 26, 2021, Axcella Therapeutics announced a new clinical program to investigate AXA1125 as a potential treatment…
On Oct. 25, 2021, Merck and Ridgeback Biotherapeutics announced the European Medicines Agency (EMA) had initiated a rolling…
On Oct. 25, 2021, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
On Oct. 21, 2021, the National Institutes of Health (NIH) announced that a booster dose of the mRNA-1273…
On Oct. 21, 2021, Ligand Pharmaceuticals announced the signing of a collaboration agreement granting China Resources Double-Crane Pharmaceutical…
On Oct. 20, 2021, Quest Diagnostics announced it had formed an agreement with the Texas Department of State…
On Oct. 19, 2021, the first investigational transplant of a genetically engineered, nonhuman kidney to a human body…
On Oct. 18, 2021, a clinical trial has found that treatment with the immunomodulator interferon beta-1a plus the…
On Oct. 18, 2021, Gilead Sciences announced that the Food and Drug Administration had approved a new low-dose…
On Oct. 18, 2021, LogicBio Therapeutics announced clinical trial results demonstrating the first-ever in vivo genome editing in…
On Oct. 18, 2021, Athenex and the Center for Cell and Gene Therapy at Baylor College of Medicine,…
On Oct. 18, 2021, Pfizer and BioNTech announced that the European Medicines Agency’s Committee for Human Medicinal Products…